Travere Therapeutics, Inc. - TVTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | Armistice Capital, LLC | 5.27% | 4,897,417 | View |
| May 15, 2026 | SCHEDULE 13G | Steven Boyd | 5.27% | 4,897,417 | View |
| Apr 30, 2026 | SCHEDULE 13G | Vanguard Capital Management | 5.09% | 4,699,424 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 4.8% | 4,278,180 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Joseph Edelman | 4.8% | 4,278,180 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 4.8% | 4,278,180 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Armistice Capital, LLC | 4.21% | 3,763,891 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Steven Boyd | 4.21% | 3,763,891 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Macquarie Group Limited | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Macquarie Management Holdings Inc | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Macquarie Investment Management Business Trust | 0.0% | 0 | View |
| Jan 08, 2026 | SCHEDULE 13G | FMR LLC | 11.7% | 10,567,303 | View |
| Jan 08, 2026 | SCHEDULE 13G | Abigail P. Johnson | 11.7% | 10,567,303 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.